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The age-dependent declines of skeletal muscle and cognitive functions often coexist in
elderly subjects. The underlying pathophysiological mechanisms share common features
of mitochondrial dysfunction, which plays a central role in the development of overt
sarcopenia and/or dementia. Dietary supplementation with formulations of essential and
branched-chain amino acids (EAA-BCAA) is a promising preventive strategy because it
can preserve mitochondrial biogenesis and function. The senescence-accelerated mouse
prone 8 (SAMP8) is considered an accurate model of age-related muscular and cognitive
alterations. Hence, we aimed to investigate the progression of mitochondrial dysfunctions
during muscular and cognitive aging of SAMP8 mice and to study the effects of a novel
EAA-BCAA-based metabolic modulator on these changes. We evaluated body condition,
motor endurance, and working memory of SAMP8 mice at 5, 9, 12, and 15 months of
age. Parallel changes in protein levels of mitochondrial respiratory chain subunits,
regulators of mitochondrial biogenesis and dynamics, and the antioxidant response, as
well as respiratory complex activities, were measured in the quadriceps femoris and the
hippocampus. The same variables were assessed in 12-month-old SAMP8 mice that had
received dietary supplementation with the novel EAA-BCAA formulation, containing
tricarboxylic acid cycle intermediates and co-factors (PD-0E7, 1.5 mg/kg/body weight/
day in drinking water) for 3 months. Contrary to untreated mice, which had a significant
molecular and phenotypic impairment, PD-0E7-treated mice showed preserved healthy
body condition, muscle weight to body weight ratio, motor endurance, and working
memory at 12 months of age. The PD-0E7 mixture increased the protein levels and the
enzymatic activities of mitochondrial complex I, II, and IV and the expression of
proliferator-activated receptor g coactivator-1a, optic atrophy protein 1, and nuclear
factor, erythroid 2 like 2 in muscles and hippocampi. The mitochondrial amyloid-b-
degrading pitrilysin metallopeptidase 1 was upregulated, while amyloid precursorin.org July 2020 | Volume 11 | Article 11711
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Frontiers in Pharmacology | www.frontiersprotein was reduced in the hippocampi of PD-0E7 treated mice. In conclusion, we show
that a dietary supplement tailored to boost mitochondrial respiration preserves skeletal
muscle and hippocampal mitochondrial quality control and health. When administered at
the early onset of age-related physical and cognitive decline, this novel metabolic inducer
counteracts the deleterious effects of precocious aging in both domains.Keywords: essential amino acids, aging, sarcopenia, cognitive impairment, tricarboxylic acid cycle, mitochondrial
respiratory chain, mitochondrial biogenesis, proteostasisINTRODUCTION
Aging is a natural multifactorial process characterized by a
gradual decrease in physiological functions, resulting in
reduced resistance to stress, high vulnerability to diseases, and
increased probability of death. Although physical difficulties can
occur independently of cognitive decline, physical deterioration
often coexists with cognitive impairment in the aged population,
with a consequent erosion of older people’s independence
(Gómez-Gómez and Zapico, 2019). The frequent association of
physical and cognitive decline has recently led to the proposal of
the so-called “motoric-cognitive risk” (MCR) syndrome
(Verghese et al., 2013), which may affect up to 10% of older
persons worldwide (Maggio and Lauretani, 2019). Whether
affected subjects are at higher risk of dementia remains a
matter of debate.
Sarcopenia, recently recognized as a disease by the World
Health Organization (Anker et al., 2016), is an age-associated
loss of skeletal muscle mass and function, leading to reduced
physical performance (Cruz-Jentoft and Sayer, 2019). It is
independently associated with comorbidities, including
cognitive impairment (Hsu et al., 2014). Sarcopenia is
recognized as a core feature of frailty syndrome (Cruz-Jentoft
and Sayer, 2019), a condition of decreased physiological reserve
mostly affecting the skeletal muscle and the brain, besides other
organs and systems, and leading to increased vulnerability to
adverse health outcomes (Clegg et al., 2013). Of note, frailty has
been recently found to enhance the risk for clinically relevant
dementia in the presence of Alzheimer’s disease (AD)-related
brain pathology (Wallace et al., 2019). The prevention of
sarcopenia and cognitive decline is a significant area of current
research as a result of their increasing prevalence in a globally
aging world. Therefore, it would be useful to investigate the
shared pathophysiological mechanism(s) of physical and
cognitive decline as potential target(s) for preventive or
therapeutic interventions.
Mitochondria are mainly responsible for energy generation
and hold a central position in cellular homeostasis, driving many
aspects of the biological aging process. Several studies pointed
toward a central role of mitochondria in aging, especially in post-
mitotic, highly energy-demanding tissues like heart, skeletal
muscle, and brain (Nilsson et al., 2019). Mitochondrial
dysfunction is a crucial pathological mechanism involved in
the etiology of sarcopenia. Several mitochondrial abnormalities
have been reported in age-related muscular atrophy andin.org 2weakness, including accumulation of mitochondrial DNA
(mtDNA) damage, impaired mitochondrial biogenesis,
dynamics, and quality control as well as reduced mitochondrial
bioenergetics, and increased oxidative stress (Rygiel et al., 2016).
Similarly, age-related decrease in mitochondrial bioenergetics,
which is paralleled by increased reactive oxidative species (ROS)
in the animal and human brain, has been linked to a
deterioration of cognitive functions and the onset of dementia
(Grimm et al., 2016; Cenini et al., 2019). Extensive research
purports that mitochondrial derangements contribute to AD
pathogenesis or possibly even initiate pathologic molecular
cascades upstream of amyloid-b (Ab) deposition in AD
(Swerdlow, 2018).
Rejuvenating strategies to counteract the aging process and favor
healthy aging (i.e., aging without related illness) have been
investigated for many years; over the past decade, numerous
studies have identified fundamental mechanisms of aging, along
with targeted interventions that temper those mechanisms in
laboratory animal models. In this context, targeting mitochondria
is considered an attractive strategy to modulate the aging process
(Valerio and Nisoli, 2015; Madreiter-Sokolowski et al., 2018). We
have previously demonstrated that a specific mixture of essential
amino acids (EAAs) enriched in branched-chain amino acids
(BCAA-enriched mixture, BCAAem) activated the eNOS/
mTORC1/PGC-1a cascade in middle-aged mice, so preserving
cardiac and skeletal muscle mitochondrial biogenesis, enhancing
physical endurance and increasing average lifespan (D’Antona
et al., 2010). Subsequently, we showed that BCAAem was able to
protect mice from rosuvastatin-induced myopathy (D’Antona
et al., 2016) and to increase oxidative fiber content and
ameliorate muscular dystrophy phenotype in mutant mdx mice
(Banfi et al., 2018). Multiple mechanisms contribute to
BCAAem-mediated skeletal muscle protection, including the
rescue of de-novo protein synthesis and reduction of protein
breakdown, and notably, improvement of mitochondrial
function and enhancement of ROS defense system (D’Antona
et al., 2016; Banfi et al., 2018). Following human pilot studies,
dietary supplementation with the BCAAem formula is emerging
as a promising treatment option in elderly subjects (Aquilani
et al., 2011; Aquilani et al., 2019). Most recently, with a
randomized trial on 155 elderly malnourished patients
(MATeR study), we demonstrated the ability of BCAAem
supplementation to improve general health, muscle mass, and
strength, as well as cognitive performance (Buondonno et al.,
2019). This study emerged that BCAAem-mediated healthJuly 2020 | Volume 11 | Article 1171
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bioenergetics in peripheral blood mononuclear cells of elderly
patients (Buondonno et al., 2019).
We investigated whether a novel BCAA-enriched EAA
formulation, with a balanced BCAA stoichiometric ratio
(leucine:isoleucine:valine 2:1:1) and added Krebs’ cycle
precursors and co-factors (referred to as PD-0E7), could boost
oxidative metabolism and contrast age-related mitochondrial
dysfunction in skeletal muscle and brain. To this aim, we used
the senescence accelerated mouse prone 8 (SAMP8) model,
which progressively develops sarcopenia (An Yun et al., 2015)
and cognitive declines with an Alzheimer–like phenotype
(Akiguchi et al., 2017) between 9 and 12 months of age. We
analyzed the effects of PD-0E7 on motor and cognitive functions
and on mitochondrial parameters in skeletal muscles and
hippocampi. Overall, our findings demonstrate that i)
pharmacological modulation of mitochondrial metabolism with
a nutraceutical intervention is a feasible approach in vivo, and ii)
the correction of mitochondrial dysfunction counteracts the
onset of age-related cognitive and muscular decline, opening
new perspectives for the achievement of healthy aging.MATERIALS AND METHODS
Animals and Dietary Supplementation
All experiments were performed in accordance with the
European Community Council Directive 2010/63/EU.
According to current Italian law (D. Lgs. n. 26/2014), the
protocol was approved by the General Direction of Animal
Health and Veterinary Drugs of the Italian Ministry of Health
with the authorization n. 131/2018-PR. Male SAMP8 mice
(SAMP8/AKR/J, ENVIGO) were housed under specific
pathogen-free (SPF) conditions with room temperature set at
22 ± 2°C and a 12-h light-dark cycle, with ad libitum access to
food (Rodents standard diet cat. 4RF25, Mucedola, Settimo
Milanese, Milan, Italy) and water. The experimental design
included four groups (n=6 mice/group) of untreated mice aged
5, 9, 12, and 15 months. Another group of 9-month-old mice
(n = 12) was randomly divided in two experimental groups,
unsupplemented, and PD-0E7-supplemented (n=6/each), the
latter receiving the PD-0E7 for 3 months (1.5 mg/g body
weight/day in drinking water). The composition of the PD-0E7
supplement (Professional Dietetics S.p.A, Milan, Italy) is detailed
in Table S1. The PD-0E7 dose was selected based on our
previous experience with the BCAAem formula (D’Antona
et al., 2010) and of the safety and efficiency of a peculiar EAA-
BCAA formula containing Krebs’ cycle precursors and co-factors
(i.e., citric, succinic, and malic acids with the same percent
composition of PD-0E7) (Tedesco et al., 2020). A decade of
knowledge shows that BCAA-based mixtures are safe in both
rodents and humans and, in particular, do not harm the liver nor
the kidney (Valerio et al., 2011; Tedesco et al., 2018). The amount
of PD-0E7 to be dissolved in water was calculated by recording
the average body weight and the average daily water
consumption of each experimental group for 2 weeks beforeFrontiers in Pharmacology | www.frontiersin.org 3starting the treatment, and regularly adjusted based on the same
parameters. Body weight was measured once a week, and water
intake was checked twice a week. Fresh PD-0E7 was replaced
three times per week. Mice were culled by cervical dislocation.
Tissues were immediately harvested and differentially stored
according to the subsequent analysis. For histochemical
analysis, tissues were frozen in liquid-nitrogen pre-cooled
isopentane and stored at −80°C; for biochemical assays, blue
native gel electrophoresis (BNGE), and Western blot analysis,
samples were snap-frozen in liquid nitrogen and stored at −80°C.
Chemicals
All chemicals and reagents were purchased from Sigma Aldrich
(Milan, Italy), unless otherwise stated.
Health Status and Behavioral Analysis
Mice were monitored weekly for general health or behavioral
changes and onset of postural abnormalities. Body condition
score (BCS) was assessed according to an established method
(Ullman-Culleré and Foltz, 1999). Kyphosis, a characteristic
dorsal curvature of the spine (frequently due to backbone
muscle weakness in elderly people and progeroid mice models)
(Harkema et al., 2016), was assessed by visual inspection. The
presence of hind limb clasping reflex (a common manifestation
of neurological or neurodegenerative disease in mice) (Lalonde
and Strazielle, 2011) was assessed suspending the mice by the tail
for 20 s and observing if they clasped their hind limbs together;
normal mice splay their limbs apart. Motor skills were evaluated
measuring endurance as previously described (Viscomi et al.,
2011) using a treadmill apparatus (Ugo Basile, Italy) with a
gradually accelerating protocol (the speed was initially set at 3.8
m/min and increased by 3 m/min every 2 min). The test was
terminated by exhaustion, which was defined by 10 falls/min into
the motivational grid. The cognitive status of SAMP8 mice was
evaluated by measuring spontaneous alternation in the Y-maze, a
test assessing the immediate spatial working memory, which
strongly relies on the hippocampus and prefrontal cortex
functions (Hölter et al., 2015). The Y-maze apparatus consists
of three arms at equal angles (30 cm length × 5 cm width × 12 cm
height). In this test, each mouse was placed in the center of the
maze facing toward one of the arms and then allowed to explore
freely for 6 min. An arm entry was counted when the hind paws
of the mouse were completely into the arm. The series of arm
entries were visually recorded, and the percentage of alternation
was calculated. A spontaneous alternation was defined as
successive entries into the three arms. The percentage of
alternation (Y-maze score) was calculated by the following
equation: % alternations = [(number of spontaneous
alternations)/(total arm entries − 2)] × 100 (Hölter et al., 2015).
Histochemistry and Biochemical Assays
Histochemical analysis of cytochrome c oxidase (COX, complex
IV) in mouse gastrocnemius muscle was carried out on 8-µm
cryostat sections as previously described (Sciacco and Bonilla,
1996). For biochemical analyses, mouse quadriceps samples were
homogenized in 10 mM phosphate buffer (pH 7.4). EnzymeJuly 2020 | Volume 11 | Article 1171
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measured spectrophotometrically as previously described in
detail (Bugiani et al., 2004).Isolation of Mitochondria and Blue Native
Gel Electrophoresis
Mitochondria from skeletal muscles were isolated by differential
centrifugation (Fernández-Vizarra et al., 2002) and resuspended in
25 mM sucrose, 75 mM sorbitol, 100 mM KCl, 0.05 mM EDTA,
5 mMMgCl2, 10 mM Tris–HCl (pH 7.4), and 10 mM H3PO4, pH
7.4 (Civiletto et al., 2015). For BNGE analysis, 100 mg of
mitochondria were resuspended in NativePAGE buffer
(Invitrogen), protease inhibitors, and 4% digitonin and
incubated for 1 h on ice before centrifuging at 20,000 g at 4°C.
Coomassie G250 at 5% final concentration was added to the
supernatants. Proteins (30 mg aliquots) were separated by pre-cast
NativePAGE 3–12% Bis-Tris gels (Thermo Fisher Scientific)
according to the manufacturer’s protocol and electroblotted on
polyvinylidene fluoride (PVDF) membranes for immunodetection
(Civiletto et al., 2015).Western Blot Analysis
Mouse quadriceps femoris and hippocampi were homogenized in
ten volumes of radioimmunoprecipitation assay (RIPA) buffer
[150 mM NaCl, 5 mM EDTA, 50 mM Tris, 1% NP-40, 0.5%
sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)] in
the presence of protease and phosphatase inhibitors, with the use
of automatic homogenizer (Omni international, Kennesaw, GA).
Samples were incubated on ice for 30 min and centrifuged at
14,000 x g for 20 min at 4°C. Protein concentration was
determined with the BCA protein assay Kit (Pierce
Biotechnology, Rockford, IL). Aliquots (20 mg each) were run
through a 4–12% SDS–polyacrylamide gel electrophoresis
(PAGE), electroblotted onto a PVDF or nitrocellulose
membrane and probed with different primary antibodies: total
oxidative phosphorylation (OXPHOS) rodent antibody cocktail
(Abcam, ab110413, dilution 1:1,000); OPA1 (Immunological
Sciences, 1:1,000); PITRM1 (ATLAS, 1:1,000); APP (Abcam,
1:1,000); GAPDH (Immunological Sciences, 1:2,000), PGC-1a
(Novus Biological, 1:1,000), p70 S6 kinase and phospho-p70 S6
kinase (Cell Signaling Technology 1:1,000), SIRT1 (Cell
Signaling Technology 1:1,000), Nrf2 (BioSource, 1:500), IDE
(Abcam 1:1,000), chemiluminescence-based immunostaining
(ECL Western Blotting Detection Kit, Amersham) was
performed. Images were acquired with the use of ChemiDoc
Imaging System apparatus (Bio-Rad Laboratories, Milan, Italy)
and analyzed with Image Lab™ software, version 6.0.1 for
Windows (Bio-Rad Laboratories, Milan, Italy).Statistical Analysis
One-way ANOVA with Tukey’s post-test for multiple
comparison or Student’s t-test were used to compare the
means among four age groups or between two groups,
respectively. Fisher Exact test was performed to evaluateFrontiers in Pharmacology | www.frontiersin.org 4significance of frequency records among four age groups. The
data were analyzed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego, CA). A linear
model fitted using generalized estimating equation (GEE)
accounting for the within-subject correlation was used to
analyze longitudinal experiments, either with Gaussian error
distribution for quantitative data or with binomial distribution
for binary events. Models were fitted using R (version 3.6.3). All
tests were two-sided and assumed a 5% significance. See text or
figure legends for details.RESULTS
SAMP8 Mice Show Age-Related Physical
and Cognitive Decline
We first performed a comprehensive characterization of age-
related changes in the general health status, as well as in motor
and cognitive abilities in male SAMP8 mice at 5, 9, 12, and 15
months of age. SAMP8 mice showed an age-dependent decrease
of the BCS (Ullman-Culleré and Foltz, 1999) (Figures 1A, B). In
particular, at 5 months of age, SAMP8 mice appeared healthy
and well-conditioned, without prominence of vertebrae and
dorsal pelvis; conversely, in the 9- and 12-month-old groups,
mice progressively appeared under-conditioned, with evident
segmentation of vertebral column and palpable dorsal pelvic
bones. At 15 months of age, SAMP8 mice looked emaciated, with
an extremely prominent skeletal structure (Figure 1A). We
observed a non-significant decrease in the body weight along
with mice age (Figure 1C) without changes in food and water
intake (not shown). SAMP8 mice showed an ever-increasing
prevalence of kyphosis that became statistically significant in the
12-month-old group (Figure 1D), with further intensification at
15 months, suggesting a progressive impairment of back muscle
mass and strength. Exercise endurance, as assessed by the
capacity to run until exhaustion during a treadmill test,
gradually and significantly diminished with age (Figure 1E).
SAMP8 mice also revealed an age-related increase in the
frequency of the hind limb clasping reflex (an index of disease
progression in various mouse models of brain lesions and
neurodegeneration, including AD) (Lalonde and Strazielle,
2011) (Figure 1F). Further, as quantified by the Y maze score
(Figure 1G), we found a substantial age-dependent reduction of
the spatial working memory (one of the early memory deficits in
human AD and ADmouse models) (Webster et al., 2014). Taken
together, these data indicate that SAMP8 mice developed an age-
related impairment of skeletal muscle function, along with
neurological and cognitive deterioration.SAMP8 Mice Show Age-Related
Mitochondrial Dysfunction in Skeletal
Muscle
Because muscular mitochondrial function declines with age
(Rygiel et al., 2016), we analyzed mitochondrial function in the
skeletal muscles of the four groups of SAMP8 mice. Significant,July 2020 | Volume 11 | Article 1171
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the oxidative phosphorylation pathway were detected by
Western blot analysis (Figure 2A) of quadriceps femoris. In
particular, the amount of the nuclear-encoded subunits of
complex I (NDUFB8, NADH:ubiquinone oxidoreductase
subunit B8), complex II (SDHB, succinate dehydrogenase
complex iron sulfur subunit B), complex III (UQCRC2,
ubiquinol-cytochrome C reductase core protein 2), and
complex V (ATP5A, ATP synthase F1 subunit alpha), as well
as the mitochondrially-encoded subunit of complex IV (MTCOI,
mitochondrial cytochrome c oxidase subunit 1) were reduced by
more than 50% from 9 months of age onwards (Figure 2A). As
previously observed in aged C57BL/6J mice (Houtkooper et al.,
2011), the master transcriptional regulator of mitochondrial
biogenesis peroxisome proliferator-activated receptor g
coactivator-1a (PGC-1a) was reduced in skeletal muscle of aged
SAMP8 mice (Figure 2A). The mitochondrial dynamin-like
GTPase optic atrophy protein 1 (OPA1), which is required for
mitochondrial fusion, cristae remodeling, and mitochondrial
respiration (Del Dotto et al., 2018) also decreased along with age
in SAMP8 quadriceps femoris (Figure 2A). Accordingly, the
enzymatic activities of individual mitochondrial respiratory chain
(MRC) complexes were also reduced when measured by
spectrophotometric assays (Figures 2B–E). In particular, theFrontiers in Pharmacology | www.frontiersin.org 5specific activity of complex I (Figure 2B) and both the oxidation
of succinate (Figure 2C) and the reduction of ubiquinone
(coenzyme Q) to ubiquinol (Figure 2D), carried out by complex
II, were decreased in the 9- and 12-month-oldmice compared to the
5-month-old mice. Interestingly, complex I enzymatic activity
seemingly recovered in the 15-month-old mice (Figure 2B),
whereas complex IV activity was not affected until the 15 months
of age, when it was significantly increased (Figure 2E). No
differences were found in the specific activity of citrate synthase
(CS) (Figure 2F), suggesting that the observed differences were not
due to a significant loss of mitochondrial mass. These data confirm
that mitochondrial deterioration is a key hallmark of aging in the
SAMP8 mouse model.SAMP8 Mice Show Age-Related
Mitochondrial Dysfunction and Impaired
APP Metabolism in Hippocampus
As the age-related cognitive impairment observed in SAMP8 mice
(Figure 1G) may rely on hippocampal dysfunction (Pallas et al.,
2008), we investigated the mitochondrial function in the
hippocampus of SAMP8 mice. As detected in the skeletal
muscles, a significant, age-related decrease in the amount of MRC
subunits was found in hippocampal homogenates (Figure 3). TheA
B D
E F G
C
FIGURE 1 | Neuromuscular and cognitive phenotypical characterization of SAMP8 mice at different ages. (A) Representative pictures of SAMP8 mice at 5, 9, 12,
and 15 months of age show a progressive appearance of signs of aging, which were quantified by means of body condition score (B), body weight (C), frequency of
kyphosis (D), and frequency of hind limb clasping reflex (E). SAMP8 mice also showed a progressive reduction in exercise endurance measured by treadmill
exhaustion test (F), which was paralleled by a decline of working memory quantified by Y-maze test (G). Statistical analyses were performed with one-way ANOVA
and Tukey’s multiple comparison test (B, C, F, G) or Fisher test (D, E). Error bars represent SEM; n=6 mice/group; **p < 0.01, ***p < 0.001.July 2020 | Volume 11 | Article 1171
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brain (Qin et al., 2009; Wang et al., 2009), were also reduced along
with age in the SAMP8 hippocampus (Figure 3). Altered amyloid
precursor protein (APP) metabolism, a crucial facet of brain aging,
has been previously described in the hippocampi of SAMP8 mice
(Pallas et al., 2008). As mitochondria are the sites in which Ab
peptides are partially processed (Mossmann et al., 2014; Brunetti
et al., 2016), we investigated whether APP level changes would
match the mitochondrial dysfunction in the aged hippocampi. We
found an age-dependent increase of APP levels in SAMP8
hippocampi (Figure 3). Interestingly, this phenomenon was
paralleled by a decrease in the levels of the pitrilysin
metallopeptidase 1 (PITRM1) (Figure 3). PITRM1 is responsibleFrontiers in Pharmacology | www.frontiersin.org 6for the degradation of the mitochondrial fraction of Ab, and the
impairment of its activity results in Ab accumulation and the
backlogging of its precursor, further leading to amyloidotic
neurodegeneration (Brunetti et al., 2016; Langer et al., 2018).
Together, these data support a mitochondrial dysfunction in the
onset of the age-associated cognitive decline of SAMP8 mice.
PD-0E7 Supplementation Prevents Age-
Related Physical and Cognitive Decline
In a diverse set of experiments, we tested whether dietary
supplementation with the PD-0E7 formula was able to counteract
the deterioration of general health status and of motor and cognitive
abilities in aged mice. Nine-month-old male SAMP8 mice (n = 12)A
B D E FC
FIGURE 2 | Age-dependent mitochondrial dysfunction in the skeletal muscle of SAMP8 mice. (A) Western blot analysis of the mitochondrial respiratory chain (MRC)
subunits ATP5A (complex V), UQCRC2 (complex III), MTCOI (complex IV), SDHB (complex II), and NDUFB8 (complex I) at different ages. The quantification of each
signal was normalized to the amount of GAPDH and represented below the images. (B–F) Enzymatic activities of MRC complex I (CI), succinate-coenzyme Q
reductase (CoQR) and succinate dehydrogenase (SDH) activities of complex II (CII), complex IV (CIV), and citrate synthase activity were measured at different ages.
All color codes as in (A). Statistical analysis was performed with one-way ANOVA and Tukey’s multiple comparison test. Error bars represent SEM; n=4 mice/group
(A) and n=6 mice/group (B–F); *p < 0.05, **p < 0.01, ***p < 0.001.July 2020 | Volume 11 | Article 1171
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Mice were then randomly divided into two experimental groups
(n=6/each), either unsupplemented or supplemented with PD-0E7
for 3 months. At the end of the experimental protocol, a second
clinical phenotyping was performed. PD-E07 dietary
supplementation did not affect food consumption and slightly
but not significantly increased water consumption in SAMP8 mice
(Table S2). Twelve-month-old, PD-0E7-treated mice appeared
healthier and better conditioned than the age-matched untreated
mice, which showed prominent kyphosis and hyposthenia of fore-
and hindlimb muscles (Figure 4A); moreover, PD-0E7-treated
mice had thick, glossy fur which was instead lost and replaced by
thinning fur in untreated animals (Figure 4A). Contrary to
untreated mice, PD-0E7-treated mice retained their BCS (time x
treatment interaction, p < 0.001; GEE) (Figure 4B) and their body
weight (time x treatment interaction, p = 0.047, GEE) (Figure 4C)
for the duration of the treatment. The frequency of kyphosis
(Figure 4D) and hind limb clasping (Figure 4F) showed non-
significant trends toward a reduction in PD-0E7-treated miceFrontiers in Pharmacology | www.frontiersin.org 7(time x treatment interaction, p = 0.2 and p = 0.128,
respectively; GEE with binomial distribution). While the
endurance performance on the treadmill test was significantly
reduced in untreated mice, it remained unchanged after the 3
months PD-0E7 treatment (time x treatment interaction, p=0.25;
GEE) (Figure 4E). Finally, contrary to untreated mice displaying
significantly reduced working memory scores at 12 months of age,
we recorded a higher working memory score upon PD-0E7
supplementation (time x treatment interaction, p < 0.001; GEE)
(Figure 4G). On the whole, these results demonstrate the efficacy
of the dietary supplementation with the PD-0E7 mixture in
counteracting age-associated muscular and cognitive decline.
PD-0E7 Treatment Preserves
Mitochondrial Biogenesis and Oxidative
Phosphorylation in the Skeletal Muscles
of SAMP8 Mice
Post-mortem examination of the skeletal muscles showed that
PD-0E7-treated SAMP8 mice had significantly higher gastrocnemiusFIGURE 3 | Progressive mitochondrial dysfunction and impaired proteostasis in the hippocampus of SAMP8 mice. Western blot analysis of hippocampal
homogenates shows an age-dependent decrease of the mitochondrial respiratory chain (MRC) subunits ATP5A (complex V or ATP synthase), UQCRC2 (complex III),
MT-COI (complex IV), SDHB (complex II), and NDUFB8 (complex I). The mitochondrial-shaping protein OPA1 was also reduced with aging. In parallel, SAMP8 mice
hippocampi showed a significant increase of amyloid precursor protein (APP) and a decrease of the pitrilysin metallopeptidase 1 (PITRM1) protein levels. The
quantification of each signal per group were normalized to the amount of GAPDH and represented below the Western blot images. Statistical analysis was
performed with one-way ANOVA and Tukey’s multiple comparison test; error bars represent SEM; n=4 mice/group; *p < 0.05, **p < 0.01, ***p < 0.001.July 2020 | Volume 11 | Article 1171
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efficacy in reducing sarcopenia. Western blot analysis on total
homogenates of quadriceps femoris showed that the amount of
phosphorylated p70 S6 kinase 1 (S6K1) was significantly
augmented in the PD-0E7-treated group compared to
unsupplemented controls (Figure 5C), demonstrating the
activation of the mTORC1/S6K1 pathway (Ma and Blenis,
2009), as we reported previously with the in vivo administration
of the BCAAem formula (D’Antona et al., 2010). We also
previously found evidence that BCAAem-activated mTOR
signaling enhances PGC-1a-mediated mitochondrial biogenesis
(D’Antona et al., 2010). Accordingly, the protein amount of PGC-
1awas significantly increased in quadriceps femoris from PD-0E7-
treated animals compared to untreated controls (Figure 5D),
together with the amount of the sirtuin family deacetylase
SIRT1, which is known to promote PGC-1a activation and
expression in the skeletal muscle (Amat et al., 2009) (Figure
5D), both suggesting that the mitochondrial biogenesis pathway
was activated upon PD-0E7 supplementation. The amounts of the
nuclear factor, erythroid 2 like 2 (NFE2L2 or Nrf2-ARE), which
regulates the expression of antioxidant genes and is involved in a
mitochondrial biogenic regulatory loop involving PGC-1a
(Gureev et al., 2019) was also increased in quadriceps femoris
from PD-0E7-treated animals (Figure 5E). The protein content of
several respiratory chain subunits, i.e., ATP5A, UQCRC2,Frontiers in Pharmacology | www.frontiersin.org 8MTCOI, and SDHB, were significantly higher than those
detected in untreated mice (Figure 5D) along with the
enzymatic activities of MRC complexes I, II, and IV
spectrophotometrically measured in total homogenates (Figure
5F). The latter was also confirmed by increased COX reaction at
the gastrocnemius muscle histochemical staining (Figure 5B).
Notably, skeletal muscles of the PD-0E7-treated group also
showed increased levels of OPA1 (Figure 5D), which,
independently from its role in mitochondrial fusion, also acts as
mitochondrial cristae shaping remodeler and a stabilizer of MRC
supercomplexes (SCs), thus impacting on respiratory efficiency
(Cogliati et al., 2013). We therefore analyzed SC assembly status in
the skeletal muscle of PD-0E7-treated versus untreated mice and
observed a shift of the free form of the complex III toward
functional SCs (Figure 5G). Altogether, these data strongly
support a role of PD-0E7 in promoting mitochondrial
biogenesis, oxidative phosphorylation, and antioxidant response
through the mTORC1/S6K1/PGC-1a pathway in the skeletal
muscle of SAMP8 mice.
PD-0E7 Treatment Preserves
Mitochondrial Biogenesis and Proteostasis
in the Brain of SAMP8 Mice
We further analyzed the hippocampi of PD-0E7-treated SAMP8
mice and untreated controls by immunoblot and, similarly to whatA B D
E F G
C
FIGURE 4 | Effect of PD-0E7 supplementation on muscular and cognitive function in aged SAMP8 mice. (A) Representative pictures of 12-month-old untreated and
PD-0E7-treated mice. The efficacy of the PD-0E7 was investigated in a longitudinal experiment comparing the behavioral scores of single mice at baseline (9M, 9
months of age) and after 3 months of supplementation (12M, 12 months of age). Control, untreated mice were also individually scored at baseline (9M) and after 3
months (12M). Treatment effects across time for body condition score (B), body weight (C), endurance capacity (E), and working memory (G) means were analyzed
with generalized estimating equation (GEE) with Gaussian error distribution. Frequency of kyphosis (D) and hind limb clasping (F) data were analyzed with GEE with
binomial distribution. Error bars represent 95% confidence interval; n=6 mice/untreated group; 5 mice/PD-0E7-treated group, due to one death after baseline
assessment. **p < 0.01; ***p < 0.001.July 2020 | Volume 11 | Article 1171
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mTORC1 pathway as demonstrated by the significant increase of
the phosphorylated form of the S6K1 protein (Figure 6A). The
transcriptional coactivator PGC-1a and the deacetylase SIRT1
were significantly upregulated in the hippocampus from PD-0E7-
treated mice (Figure 6B), with a consistent increase of the levels of
several MRC subunits (ATP5A, UQCRC2, MTCOI, SDHB,
NDUFB8). The OPA1 protein was also upregulated in the
hippocampus of PD-0E7-supplemented SAMP8 mice (Figure
6B). Interestingly, treated animals also showed increased levels
of the mitochondrial Ab scavenger PITRM1 and of the insulin-
degrading enzyme (IDE), a protease involved in the degradation of
Ab peptides (Kurochkin and Goto, 1994) that can be induced by
SIRT1-mediated mechanisms (Corpas et al., 2017) (Figure 6C)Frontiers in Pharmacology | www.frontiersin.org 9which was paralleled by a decrease in the amount of APP (Figure
6C). Collectively, these data suggest that dietary supplementation
with PD-0E7 could increase mitochondrial biogenesis and regulate
amyloid proteostasis through the activation of the mTORC1/
S6K1/PGC-1a pathway in SAMP8 mice.DISCUSSION
In the present study, we provide evidence of the beneficial effect of a
novel nutritional intervention, acting as a metabolic inducer, in
rescuing age-related motor and cognitive function in senescent
mice. The reciprocal links between muscle and brain dysfunctions
in aging have recently led to the proposal of the “motoric-cognitiveJuly 2020 | Volume 11 | Article 117A B
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FIGURE 5 | Effect of PD-0E7 on mitochondrial function in skeletal muscle of aged SAMP8 mice. (A) Representative pictures of gastrocnemius muscles of untreated
and PD-0E7-treated mice; quantification of muscle weight/body weight is shown on the right (blue bars, untreated mice, red bars, PD-0E7-treated mice).
(B) Representative image of histochemical COX-IV staining in the gastrocnemius muscle of untreated and PD-0E7-treated SAMP8 mice. (C) Western blot analysis of
phosphorylated p70 S6 kinase 1 (p-S6K) and total S6K in quadriceps femoris; quantification of pS6K/S6K ratio is shown below the image. (D) Western blot analysis
of PGC-1a, SIRT1, OPA1, and of the respiratory chain subunits ATP5A, UQCRC2, MTCOI, and SDHB in quadriceps femoris; relative quantification of proteins to
GAPDH levels is shown on the right. (E) Western blot analysis of NRF2-ARE in quadriceps femoris, with quantification relative to GAPDH shown below the image.
(F) Biochemical analysis of the enzymatic activities of the mitochondrial respiratory chain (MRC) complex I (CI), complex II (CII), and IV (CIV) in quadriceps femoris PD-
0E7 treated mice compared to untreated controls. (G) Blue native gel electrophoresis on isolated, digitonin-solubilized mitochondria from quadriceps femoris of
untreated, and PD-0E7-treated mice showed a stabilization of the complex III into supercomplexes (SC); immunoblot was performed with UQCRFS1 antibody;
quantification is shown on the right. All color codes as in (A). Statistical analysis was performed with Student’s t test. Error bars represent SEM; n=6 mice/group;
*p < 0.05, **p < 0.01, ***p < 0.001.1
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(Verghese et al., 2013; Maggio and Lauretani, 2019) and strongly
predicting the risk of developing various type of dementia, including
AD, and physical frailty (Lauretani et al., 2017). Therefore,
concurrently targeting the interlinked domains of the pathological
“brain-muscle loop” could be crucial for preserving homeostasis and
preventing the leading causes of disability in the elderly. There are
currently no adequate pharmacological or nutritional interventions
for sarcopenia and cognitive decline. We used the SAMP8 mouse
strain—which is prone to accelerated aging with impairments
affecting both muscle and brain—to investigate the shared
pathophysiological mechanism(s) of physical and cognitive
decline, with a particular focus on mitochondrial derangements,
and to explore the effectiveness of a novel metabolic modulator in
preventing these geriatric conditions.
It has been reported that SAMP8 mice spontaneously develop
a pre-sarcopenic status at 8 months of age, that results in overt
sarcopenia at 10–12 months of age (Sousa-Victor et al., 2014; An
Yun et al., 2015), as well as progressive neurodegenerative
changes between 6 and 12 months of age, reminiscent of the
pathological shift from aging to dementia of sporadic AD (Pallas
et al., 2008; Akiguchi et al., 2017). To identify the proper timing
of intervention at the early onset of motor and cognitive
impairment, we first performed an in-depth phenotypical
characterization of the SAMP8 mice, by recording established
scores of their general health status, as well as of their motor and
cognitive skills, at 5, 9, 12, and 15 months of age. In line with
previous studies (Guo et al., 2015; Griñán-Ferré et al., 2018) we
observed an age-dependent physical, neuromuscular, and
cognitive decline in this mouse strain. In particular, the early
signs of inadequate general health conditions were detectable at 9
months of age, with a trend in the reduction of BCS, as well as in
the increased frequency of kyphosis (a sign accompanying age-Frontiers in Pharmacology | www.frontiersin.org 10associated loss of muscle mass in mice) (Harkema et al., 2016)
and hind limb clasping (a sign of neurological dysfunction also
observed in AD animal models) (Lalonde and Strazielle, 2011).
These changes were significant at 12 months of age and further
worsened with aging. A marked reduction of exercise tolerance
was observed as early as at 9 months of age, with a subsequent
further decline, while working memory was significantly
impaired from the age of 12 months onwards.
By post-mortem examination, such deteriorations evolved in
parallel with a progressive impairment of the mitochondrial
function in critical tissues. The age-dependent reduction of
PGC-1a and of MRC subunits was mirrored by the decrease of
the activity of complex I, complex II, and complex IV in skeletal
muscles. Interestingly, we found that, despite the similar amount
of MRC subunits, muscle mitochondria of the 15-month-old
group had higher activities of the respiratory chain complexes I
and IV than the 12-month-old ones. Of notice, SAMP8 mice are
characterized by a shortened life span, with median and
maximum life span expectancy of approximately 10 and 16
months, respectively, the latter reached by 20% of the SAMP8
mouse population (Porquet et al., 2013), though possibly
influenced by housing and feeding conditions. Therefore, the
15-month-old group represents the long-lived portion of the
SAMP8 colony, sharing some similarities with long-lived
individuals. In particular, mitochondria from skin biopsies of
long-lived humans (i.e., centenarians) are defective but maintain
a higher bioenergetic efficiency compared with old individuals,
possibly due to increased autophagic processes (Sgarbi et al.,
2014). These phenomena could possibly explain the preserved
MRC activities in the 15-month-old group. We also identified an
age-dependent down-regulation of the mitochondria-shaping
protein OPA1 in the quadriceps femoris of SAMP8 mice, as
reported in muscles of sarcopenic rodents (Ibebunjo et al., 2013)A B C
FIGURE 6 | Effects of PD-0E7 on mitochondrial function in the hippocampus of aged SAMP8 mice. (A) Western blot analysis of phosphorylated p70 S6 kinase 1 (p-
S6K) and total S6K in hippocampal homogenates; quantification of pS6K/S6K ratio is shown below the image (blue bars, untreated mice, red bars, PD-0E7-treated
mice). (B) Western blot analysis of PGC-1a, SIRT1, OPA1, and the mitochondrial respiratory chain (MRC) subunits ATP5A, UQCRC2, MTCOI, SDHB, NDUFB8 in
mouse hippocampi; relative quantification of protein to GAPDH levels is shown on the right. (C) Western blot analysis of amyloid precursor protein (APP), pitrilysin
metallopeptidase 1 (PITRM1), and insulin-degrading enzyme (IDE) protein levels and quantification relative to GAPDH levels. All color codes as in (A). Statistical
analysis was performed with unpaired Student’s t test. Error bars represent SEM, n=4 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001.July 2020 | Volume 11 | Article 1171
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and defects of mitochondrial dynamics correlate with muscle
mass loss and muscle force drop (Joseph et al., 2012; Tezze
et al., 2017).
The brain is a high-energy-demanding tissue, in which age-
related mitochondrial dysfunctions are detrimental (Boveris and
Navarro, 2008). Of note, a recent large systematic analysis showed
altered expression of genes implicated in mitochondrial function
in blood and brain areas of patients with mild cognitive
impairment (a condition that is often, but not always, a
transitional phase from cognitive changes of normal aging to
those typically found in dementia) and of AD patients (Li et al.,
2018). The so-called “mitochondrial cascade hypothesis” proposes
that mitochondrial dysfunction is the primary event in AD
pathology. Numerous experiments proved that the accumulation
of Ab in mitochondria begins before the incidence of extracellular
deposition (a view that integrates the amyloid cascade hypothesis),
and this leads to mitochondrial dysfunction with increased
oxidative stress, impaired mitochondrial dynamics and drop in
ATP production, with following synaptic dysfunction, apoptosis,
and neurodegeneration (Swerdlow, 2018). Other studies sustain
that mitochondrial dysfunction initiates upstream of Ab
deposition, suggesting a primary mitochondrial cascade
hypothesis (Swerdlow, 2018). Bioenergetic failure, therefore, lies
at the core of Alzheimer’s disease pathophysiology.
Although apparently lacking neurofibrillary tangles (one of
the pathological hallmarks of AD), SAMP8 mouse brain shows
many neuropathological signatures of AD, including APP
overproduction, abnormal Ab accumulation and impaired Ab
clearance, hyperphosphorylation of tau protein, increased
oxidative stress, and gliosis, especially in the hippocampus
(Pallas et al., 2008; Morley et al., 2012; Akiguchi et al., 2017).
These neuropathological changes increase with age and correlate
with the early and progressive decline of learning and memory
abilities in SAMP8 mice (Akiguchi et al., 2017). Thus, this strain
is considered a good preclinical model for studying the earliest
neurodegenerative changes triggered by age‐related events and
associated with sporadic AD (Akiguchi et al., 2017). In
agreement with the various learning and memory deficits
reported in SAMP8 mice (Morley et al., 2012), we observed an
age-dependent impairment in immediate spatial working
memory, which relies on the hippocampus and its connections
with the prefrontal cortex (Hölter et al., 2015). We further
demonstrated a progressive, significant reduction of the levels
of various MRC subunits in the hippocampus, which occurred in
parallel to the decrease of PGC-1a and OPA1 levels, as well as to
APP accumulation and PITRM1 reduction. PITRM1 (also
known as presequence peptidase, PreP) is a mitochondrial
matrix enzyme that digests the N-terminal peptides of proteins
imported across the inner mitochondrial membrane, after they
have been cleaved off from precursor proteins by the
mitochondrial matrix peptidase (MMP) (Alikhani et al., 2011).
These peptides are amphiphilic species, with a polar, positively
charged, arginine-rich side, opposite to an apolar side. If not
cleared from the mitochondrial matrix, they may act as
detergent-like, toxic agents, forming pores in the membranesFrontiers in Pharmacology | www.frontiersin.org 11dissipating the mitochondrial membrane potential. It was
demonstrated that PITRM1 also act as scavenger digesting the
mitochondrial fraction of Ab. Of note, impaired PITRM1 activity
has been detected in the brain from transgenic AD mice and in
the temporal lobes of AD patients compared with non-AD age-
matched controls (Alikhani et al., 2011). Further investigation
has confirmed that the accumulation of Ab exerts a feedback
inhibition on MPP and PITRM1 activity, leading to impaired
mitochondrial presequence processing and accumulation of
precursor proteins, supporting its central role in the age-
dependent vicious cycle of mitochondrial dysfunction in AD
(Mossmann et al., 2014). We previously demonstrated that a 50%
reduction of PITRM1 amount in the hemizygous PITRM1+/−
mouse causes slowly progressive, multisystem neurological
impairment, with age-dependent accumulation in the brain of
both Ab42 (the key amyloidogenic Ab species in AD) and APP
(Brunetti et al., 2016). It has been recently also observed that
cerebral organoids generated from PITRM1−/− human induced
pluripotent stem cells display increased APP levels and Ab42/
Ab40 ratio, as well as pathological features of AD, including
protein aggregation, tau hyperphosphorylation, and neuronal
death (Pérez et al., 2020). Our present data showed that the
reduction of PITRM1 is paralleled by increased APP and
decreased MRC subunit levels in the hippocampus of SAMP8
mice, possibly contributing to mitochondrial dysfunction and to
the onset of cognitive symptoms.
A body of research efforts is currently devoted to boosting
mitochondrial bioenergetics as novel therapeutic approaches to
treat sarcopenia (Waltz et al., 2018), cognitive decline, and AD
(Lejri et al., 2019; Perez Ortiz and Swerdlow, 2019). Given that
these conditions will continue to rise worldwide alongside with
the population aging, a focus on prevention is urgently needed.
Studies in preclinical models are necessary to investigate the
effects of compounds that could sustain age-related skeletal
muscle and brain dysfunctions. We took advantage of our
long-standing experience with the BCAAem formula, which
preserves skeletal muscle health by targeting mitochondrial
function via the mTORC1/PGC-1a pathway (D’Antona et al.,
2010; D’Antona et al., 2016; Banfi et al., 2018), and has recently
proven to be effective in improving muscular and cognitive
performance in elderly subjects (Buondonno et al., 2019). We
recently demonstrated that adding tricarboxylic acid cycle
intermediates and co-factors to an EAA-BCAA mixture
increases oxidative metabolism much more than the previous
formula and potentiates its protective effects against
mitochondrial dysfunction (Tedesco et al., 2020). Here we
tested the novel EAA formulation PD-0E7, with an optimized
stoichiometric ratio of BCAAs, and added Krebs’ cycle
precursors and co-factors, in SAMP8 senescent mice.
We found that supplementation with PD-0E7 in the temporal
window between 9- and 12-month of age beneficially affected the
whole body and counteracted the age-related signs of
neuromuscular and cognitive decline of SAMP8 mice. These
effects were accompanied by increased activation of the
mTORC1 pathway (as demonstrated by increased S6K1
phosphorylation) both in skeletal muscle and in hippocampusJuly 2020 | Volume 11 | Article 1171
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role in exercise-mediated health benefits on physical and
cognitive performance (Watson and Baar, 2014). In particular,
increased mTORC1 signaling is responsible for changes in
skeletal muscle growth that occur in response to exercise in
rodents and humans (Goodman, 2014; Goodman, 2019). In turn,
exercise—which in normal mice extends health span (i.e. healthy
disease-free life span)—remains the only currently available
intervention to mitigate and even reverse the age-related
decline in muscle mass and function of sarcopenia. Although
reduction of mTORC1 signaling is generally accepted as a
fundamental mechanism implied in the pro-longevity effects of
multiple strategies, including calorie restriction, intermittent
fasting, and drug treatment (e.g., rapamycin), studies with
rapamycin and related drugs, or genetic mTORC1 inhibition
showed deleterious effects on muscle mass and functions (see
Adegoke et al., 2019 and reference herein for review) (Adegoke
et al., 2019). Notably, in older people mTORC1 becomes less
responsive to contraction-induced activation compared with
young adults (Fry et al., 2011). Additionally, exercise
upregulates PGC-1a, hence counteracting its age-related
decline (Gill et al., 2018). Activation of mTORC1 favors PGC-
1a coactivation of its own promoter (Cunningham et al., 2007)
and positively correlates with cellular oxidative capacity (Schieke
et al., 2006). Accordingly, we found that chronic treatment with
PD-0E7 increased PGC-1a protein levels and upregulated
several MRC subunits, also enhancing their activity in mouse
skeletal muscle and hippocampus. Raised SIRT1 levels in both
tissues of PD-0E7-treated mice could further amplify the
mitochondrial responses by deacetylating and activating PGC-
1a (Dominy et al., 2010). Finally, skeletal muscle of PD-0E7-
treated mice displayed augmented levels of Nrf2, a transcription
factor that activates antioxidant genes upon binding to
antioxidant-responsive elements (ARE) motifs in their
promoters (Ma, 2013). Increased mitochondrial respiration can
augment ROS production if appropriated mitochondrial quality
control lacks. Although optimal levels of ROS act as essential
biological signals regulating various physiological processes
(Ristow and Schmeisser, 2014), excess ROS levels can damage
cellular components contributing to age-related pathology.
Notably, both PGC-1a and Nrf2 are involved in mitochondrial
biogenesis and in the endogenous antioxidant response, and a
positive regulatory loop has been described between the two
factors, overall contributing to maintain mitochondrial mass and
redox homeostasis (Ryoo and Kwak, 2018). Hence, simultaneous
activation of the PGC-1a and Nrf2 pathways is being considered
one of the most promising strategies in gerontoprotection
(Gureev et al., 2019).
PD-0E7-supplementedmice showed higher muscle weight when
compared to the age-matched untreated controls. The preserved
exercise endurance observed in the 12-month-old PD-0E7-
supplemented mice might be explained by the increased activity
of MRC enzymes (CI, CII, and CIV complexes) and by a substantial
shift toward oxidative COX-positive fibers in the gastrocnemius
muscle. Interestingly, the protein levels of OPA1 were significantlyFrontiers in Pharmacology | www.frontiersin.org 12increased in the muscle of PD-0E7-treated group. In addition to its
role in mitochondrial fusion, OPA1 regulates mitochondrial cristae
remodeling by promoting the juxtaposition of the cristae
membranes (Varanita et al., 2015; Del Dotto et al., 2018). Cristae
tightness, in turn, determines the assembly and stability of
respiratory chain complexes into SC structures (Cogliati et al.,
2013). These functional quaternary structures increase the
electron flow channeling during respiration, minimizing electron
leaks (Acin-Perez and Enriquez, 2014; Enriquez and Lenaz, 2014),
and stabilizing individual respiratory chain complexes such as
complex III (Acıń-Pérez et al., 2004), thus affecting mitochondrial
respiratory efficiency. Indeed, OPA1 overexpression optimizes the
ATP production and ameliorates mitochondrial dysfunction in vivo
(Civiletto et al., 2015). The PD-0E7-mediated increase of OPA1
content in skeletal muscles may explain the improved stabilization
of the CIII holocomplex into SCs that we detected by BNGE
analysis of the quadriceps femoris of PD-0E7-treated SAMP8
mice. A similar link between OPA1 levels, SC organization, and
muscle mass was recently described in humans (Tezze et al., 2017).
Alterations in SCs have been described in brain and muscle during
aging, and interestingly, besides increasing individual MRC
subunits, exercise affects the stoichiometry of SC formation in old
age (Greggio et al., 2017). In particular, exercise training promoted
the redistribution of CIII into SCs in vastus lateralis muscle of
sedentary older subjects (Greggio et al., 2017). Altogether, these
observations suggest that PD-E07 might act as an exercise mimetic
in elderly people.
Mice having received PD-0E7 supplementation for 3months not
only did not show the decline in short-term working memory
observed in untreated animals, but instead showed a significantly
higher memory score when compared to their baseline (at 9 months
of age) conditions. Interestingly, SIRT1– whose content is reduced
in the cortex of aged SAMP8mice (Pallàs et al., 2008) and increased
by PD-0E7 treatment in the hippocampus of 12-month-old SAMP8
mice compared to untreated mice—is critical for maintaining the
physiological acquisition and consolidation of short- and long-term
hippocampus-dependent memories (Michán et al., 2010). We also
provided substantial evidence that PD-0E7 treatment enhanced the
hippocampal mitochondrial quality control system upregulating
PITRM1 and IDE levels. Both PITRM1 and IDE belong to the
pitrilysin M16 family of proteases, and their activity is lost in AD
brain (Alikhani et al., 2011; Leal et al., 2013). The PD-0E7 increased
PITRM1 and IDE could account for the observed reduction in
hippocampal APP content. Remarkably, PGC-1a also controls Ab
degradation through regulation of the IDE gene expression in the
brain (Leal et al., 2013). As such, the PD-0E7-mediated induction of
PGC-1a could be a strategic chance not only to boost the oxidative
phosphorylation, that restores the ATP levels, and to reduce
oxidative stress, but also to favor the mitochondrial proteostasis,
which is impaired in aging and in neurodegenerative disease (Leal
et al., 2013). Similarly, a transgenic AD mouse model
overexpressing PITRM1 in neuronal mitochondria had reduced
Ab levels, improvement of mitochondrial health and synaptic
density in the cerebral cortex and hippocampus, as well as
preserved spatial learning and memory deficits. These findingsJuly 2020 | Volume 11 | Article 1171
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therapeutic avenue for the treatment of AD (Fang et al., 2015).
Enhancing mitochondrial proteostasis in the brain can represent an
important therapeutic strategy to delay Ab-related toxicity
(Sorrentino et al., 2017). Notably, the present findings show that
an efficient enhancement of PITRM1-mediated brain proteostasis
can be accomplished with a nutraceutical intervention, which
deserves to be investigated for its potential role in preventing and/
or reducing amyloid pathology.
In conclusion, dietary supplementation with the metabolic
modulator PD-0E7 rejuvenates mitochondria and efficiently
counteracts a plethora of deleterious effects exerted by
premature aging in critical tissues (Figure 7), thus potentially
representing a new efficacious and safe intervention to prevent
disability and frailty in subjects at high motoric-cognitive risks.DATA AVAILABILITY STATEMENT
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Sousa-Victor, P., Gutarra, S., Garcıá-Prat, L., Rodriguez-Ubreva, J., Ortet, L.,
Ruiz-Bonilla, V., et al. (2014). Geriatric muscle stem cells switch reversible
quiescence into senescence. Nature 506, 316–321. doi: 10.1038/
nature13013
Swerdlow, R. H. (2018). Mitochondria and Mitochondrial Cascades in Alzheimer’s
Disease. J. Alzheimer’s Dis. 62, 1403–1416. doi: 10.3233/JAD-170585
Tedesco, L., Corsetti, G., Ruocco, C., Ragni, M., Rossi, F., Carruba, M. O., et al.
(2018). A specific amino acid formula prevents alcoholic liver disease in
rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 2018, G566–G582.
doi: 10.1152/ajpgi.00231.2017
Tedesco, L., Rossi, F., Ragni, M., Ruocco, C., Brunetti, D., Carruba, M. O., et al. (2020).
A special amino-acid formula tailored to boosting cell respiration prevents
mitochondrial dysfunction and oxidative stress caused by doxorubicin in mouse
cardiomyocytes. Nutrients 12, 2020. doi: 10.3390/nu12020282
Tezze, C., Romanello, V., Desbats, M. A., Fadini, G. P., Albiero, M., Favaro, G.,
et al. (2017). Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass,
Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence.
Cell Metab. 25, 1374–1389.e6. doi: 10.1016/j.cmet.2017.04.021
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